Immatics N.V. (IMTX)
NASDAQ:IMTX
Want to see IMTX full AI Analyst Report?
IMTX Stock Chart & Stats
$11.17
<$0.01(0.14%)
At close: 4:00 PM EST
$11.17
<$0.01(0.14%)
Day’s Range― - ―
52-Week Range$4.93 - $12.41
Previous CloseN/A
Volume408.80K
Average Volume (3M)453.41K
Market Cap
$1.56B
Enterprise Value$1.06B
Total Cash (Recent Filing)$454.04M
Total Debt (Recent Filing)$15.10M
Price to Earnings (P/E)―
Beta1.35
Next Earnings
Aug 19, 2026EPS Estimate
-0.49Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.71
Shares Outstanding134,096,570
10 Day Avg. Volume605,078
30 Day Avg. Volume453,413
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)2.26
Price to Sales (P/S)22.65
P/FCF Ratio-6.21
Enterprise Value/Market Cap0.68
Enterprise Value/Revenue28.32
Enterprise Value/Gross Profit28.32
Enterprise Value/Ebitda-4.98
Forecast
1Y Price Target
$19.03Price Target Upside70.35% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-1.68
Revenue Forecast (FY)$37.35M
Bulls Say, Bears Say
Bulls Say
Low Leverage / Strong Balance SheetExtremely low leverage provides durable financial flexibility to fund multi-year, capital-intensive clinical programs without immediate refinancing pressure. This reduces short-term insolvency risk, enables strategic R&D investment choices, and supports milestone-driven development through pivotal readouts.
Proprietary Discovery Platform (XPRESIDENT)Owning a peptide-centric discovery engine creates a sustainable competitive advantage by increasing target identification efficiency and enabling multiple modality applications (TCRs, cell therapies, bispecifics). This platform-driven R&D model supports repeatable pipeline generation and potential long-term franchise value.
Clinical And Regulatory Momentum For PRAMEAdvancing a Phase 3 program with regulatory designations and a planned BLA creates a tangible commercialization pathway. These durable milestones can convert R&D investment into first-to-market positioning for PRAME-targeted therapies, expanding addressable indications and strengthening long-term revenue prospects if trials succeed.
Bears Say
Sustained Negative Cash FlowLarge, sustained operating and free cash outflows materially elevate funding risk for ongoing trials and commercialization activities. Over time this necessitates external financing or partnerships, increasing dilution or dependency on collaborators and constraining optionality for independent program advancement.
Sharp Revenue Decline And Heavy LossesA notable drop in revenue paired with very large negative margins signals weak near-term internal funding capacity and high operating leverage. Persistent losses erode equity returns and increase the likelihood of dilutive capital raises, complicating long-term planning and shareholder value creation.
Revenue Concentration And Collaboration VolatilityHeavy reliance on collaboration and milestone income makes top-line cash inflows lumpy and dependent on partner choices. Such volatility complicates multi-year budgeting for trials, elevates execution risk, and can force reactive financings or partnership concessions when milestone timing shifts.
Immatics News
IMTX FAQ
What was Immatics N.V.’s price range in the past 12 months?
Immatics N.V. lowest stock price was $4.93 and its highest was $12.41 in the past 12 months.
What is Immatics N.V.’s market cap?
Immatics N.V.’s market cap is $1.56B.
When is Immatics N.V.’s upcoming earnings report date?
Immatics N.V.’s upcoming earnings report date is Aug 19, 2026 which is in 85 days.
How were Immatics N.V.’s earnings last quarter?
Immatics N.V. released its earnings results on May 12, 2026. The company reported -$0.5 earnings per share for the quarter, missing the consensus estimate of -$0.461 by -$0.04.
Is Immatics N.V. overvalued?
According to Wall Street analysts Immatics N.V.’s price is currently Undervalued.
Does Immatics N.V. pay dividends?
Immatics N.V. does not currently pay dividends.
What is Immatics N.V.’s EPS estimate?
Immatics N.V.’s EPS estimate is -0.49.
How many shares outstanding does Immatics N.V. have?
Immatics N.V. has 134,096,570 shares outstanding.
What happened to Immatics N.V.’s price movement after its last earnings report?
Immatics N.V. reported an EPS of -$0.5 in its last earnings report, missing expectations of -$0.461. Following the earnings report the stock price went down -1.3%.
Which hedge fund is a major shareholder of Immatics N.V.?
Currently, no hedge funds are holding shares in IMTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Immatics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$19.03 (70.35% Upside)
$19.03 (70.35% Upside)
Blogger Sentiment
Bullish
IMTX Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 1.2M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▼ 7.4%
Last 30 Days ▼ 7.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
123.46%
12-Months-Change
Fundamentals
Return on Equity
-45.47%
Trailing 12-Months
Asset Growth
-9.70%
Trailing 12-Months
Company Description
Immatics N.V.
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its ACTengine product candidates are in Phase I clinical trials, which include IMA201 that targets melanoma-associated antigen 4 or 8 in patients with solid tumors; IMA202 that targets melanoma-associated antigen 1 in patients with various solid tumors, including squamous non-small cell lung carcinoma and hepatocellular carcinoma; and IMA203 that targets preferentially expressed antigen in melanoma in adult patients with relapsed and/or refractory solid tumors, as well as IMA204, which is in preclinical studies that targets tumor stroma cell. The company's TCR Bispecifics product candidates, which are in preclinical studies include IMA401, a cancer testis antigen for the treatment of solid tumors; and IMA402 for the treatment of solid tumors. It also develops IMA101 for the treatment of cancer; and IMA301, an allogenic cellular therapy product candidate. The company has a strategic collaboration agreement with GlaxoSmithKline Intellectual Property Development Limited to develop novel adoptive cell therapies targeting multiple cancer indications; MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Switzerland LLC to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.
IMTX Stock 12 Month Forecast
Average Price Target
$19.03
▲(70.35% Upside)
Technical Analysis
Ownership Overview
―
Insiders
10.89% Mutual Funds
61.55% Other Institutional Investors
26.91% Public Companies and
Individual Investors